Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 8/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.40 |
| ▸ | SKP1 | P63208 | 2/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623035 | 0.90 | CSNK1D (0.43) | CSNK1DCSNK1EGPR119CKS1BSKP1 | |
| SCHEMBL30623021 | 0.90 | CSNK1E (0.44) | CSNK1DCSNK1EGPR119CKS1BSKP1 | |
| SCHEMBL17382842 | 0.88 | CSNK1E (0.52) | CSNK1DCSNK1ECKS1BSKP1SKP2 | |
| SCHEMBL26645726 | 0.88 | MEN1 (0.46) | CSNK1DCSNK1ECKS1BSKP1SKP2 | |
| SCHEMBL26645466 | 0.85 | CSNK1D (0.49) | CSNK1DCSNK1EGPR119USP30CKS1B | |
| SCHEMBL26645301 | 0.84 | CSNK1D (0.44) | CSNK1DCSNK1EGPR119USP30CKS1B | |
| SCHEMBL26645250 | 0.83 | CSNK1D (0.48) | CSNK1DCSNK1EGPR119USP30CKS1B | |
| SCHEMBL26645904 | 0.82 | CSNK1E (0.55) | CSNK1DCSNK1E | |
| SCHEMBL26645681 | 0.82 | CSNK1E (0.48) | CSNK1DCSNK1EGPR119CKS1BSKP1 | |
| SCHEMBL26645019 | 0.82 | CSNK1D (0.47) | CSNK1DCSNK1EGPR119CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-07 | — | — | US | disclosed |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| WO-2015144799-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | ROS1, NOX1, NOX5 | CSNK1D 1280/4885CSNK1E 1301/4885GPR119 2103/4885 |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | ROS1, NOX1, NOX5 | CSNK1D 1280/4885CSNK1E 1301/4885GPR119 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.